|
COPZ1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.68229907571549E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.30640009499939E-10 |
| Normal-vs-Stage2 |
1.154990E-01 |
| Normal-vs-Stage3 |
1.53188572937779E-12 |
| Normal-vs-Stage4 |
1.65334412827178E-12 |
| Stage1-vs-Stage2 |
2.738300E-03 |
| Stage1-vs-Stage3 |
2.421700E-02 |
| Stage1-vs-Stage4 |
2.776000E-04 |
| Stage2-vs-Stage3 |
2.962900E-04 |
| Stage2-vs-Stage4 |
1.53353999999828E-05 |
| Stage3-vs-Stage4 |
1.384150E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.79312162077395E-12 |
| Normal-vs-AfricanAmerican |
7.540100E-03 |
| Normal-vs-Asian |
2.5445201501384E-12 |
| Caucasian-vs-AfricanAmerican |
2.301800E-01 |
| Caucasian-vs-Asian |
4.101400E-01 |
| AfricanAmerican-vs-Asian |
1.618430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.21949994547066E-09 |
| Normal-vs-Female |
1.3417000843674E-10 |
| Male-vs-Female |
7.490400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.94669988199337E-10 |
| Normal-vs-Age(41-60Yrs) |
2.2863999582512E-09 |
| Normal-vs-Age(61-80Yrs) |
5.82450000452539E-08 |
| Normal-vs-Age(81-100Yrs) |
2.501400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.231200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.897600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.167200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.490400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.805000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.285600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.15210000428689E-08 |
| Classical-VS-Follicular |
8.00060000472058E-08 |
| Classical-VS-Other |
6.933400E-01 |
| Classical-VS-Normal |
1.88449256199874E-12 |
| Tall-VS-Follicular |
2.44249065417534E-15 |
| Tall-VS-Other |
2.758200E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
4.816200E-02 |
| Follicular-VS-Normal |
2.220400E-01 |
| Other-VS-Normal |
6.026600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.35619999961112E-07 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.66770000429051E-09 |
|
|
